<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: CD44 is a transmembrane <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> and is associated with cell-matrix and cell-cell interactions </plain></SENT>
<SENT sid="1" pm="."><plain>CD44 expression was shown to be relevant to <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumour progression</z:e> in various types of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The objective of this study was to investigate the relationship between the expression levels of the standard form of CD44 (CD44s), and clinicopathological characteristics in a subset of colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: A total of 96 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> were retrieved from the archives at the Department of Pathology at King Abdulaziz University, Jeddah, KSA </plain></SENT>
<SENT sid="4" pm="."><plain>Immunohistochemistry was performed using antibodies to CD44s </plain></SENT>
<SENT sid="5" pm="."><plain>A cut-off of &lt;10% of positive neoplastic cells was used to define low expression, 10-50% to define moderate expression and &gt;50% to define extensive expression </plain></SENT>
<SENT sid="6" pm="."><plain>Statistical tests were used to determine the association of CD44s with clinicopathological characteristics in a subset of colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> and survival </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Immunostaining results showed that there was no association between C44 immunoexpression and age of patients, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> grade, depth of invasion, vascular invasion, recurrence and survival </plain></SENT>
<SENT sid="8" pm="."><plain>CD44s immunolabelling was found to have an association with nodal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and to be an independent predictor of nodal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Loss of CD44s immunolabelling in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> is an independent favourable predictor of regional lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>On the other hand, CD44s loss has no significant association with disease recurrence or survival </plain></SENT>
<SENT sid="11" pm="."><plain>Extensive in vivo and in vitro molecular studies are required to elucidate the possible mechanistic association of CD44s with <z:e sem="disease" ids="C0598935" disease_type="Neoplastic Process" abbrv="">tumour initiation</z:e>, progression, invasion and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> in primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, and in nodal and distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
</text></document>